- Aleafia Health (TSX:ALEF) subsidiary, Emblem Germany, has submitted its application for the EU Good Manufacturing Practices certification
- If approved, Emblem Germany will be able to produce and export pharmaceutical-grade cannabis to the European Union
- Aleafia’s licensed Paris facility was built to meet EU GMP certification standards, and has had a new expansion approved
- The company does not know how long certification will take, but is preparing for an eventual facility inspection regardless
- Aleafia Health is up 9.52 per cent, and is currently trading for $0.69 per share
Aleafia Health (TSX:ALEF) subsidiary, Emblem Germany, has submitted its cannabis facility for the EU’s Good Manufacturing Practices certification.
If approved, the certification will allow Aleafia’s Paris facility to produce and export pharmaceutical-grade cannabis to the EU.
The company purpose-built the Paris facility to meet the high standards and requirements of the EU GMP certification. Only days ago, the facility received the go-ahead from Health Canada for a 30,000 square foot expansion on the facility.
Cannabis production operations at the Phase II expansion started on May 6, 2020, three days after receiving the licence amendment. While the company does not know how long certification will take, it is already preparing for an eventual facility inspection.
Aleafia Health’s CEO, Geoffrey Benic, commented on the possibilities presented by the facility and EU GMP application.
“The state-of-art expansion of the Paris facility, purpose built to meet EU-GMP standards, creates a unique competitive advantage with significant barriers to entry.
“We look forward to leveraging the skillsets of our strong partner Acnos Pharma, along with our management team’s in-house EU-GMP expertise,” he said.
Aleafia and German pharmaceutical company, Acnos Pharma, have a joint venture which owns an interest in Emblem Germany.
Aleafia and Acnos have previously worked together to build, certify, and operate multiple EU GMP-certified production facilities in Holland, Germany, and Northern America.
Later this month, Acnos will complete a new pharmaceutical production and supply chain facility in Aachen Brand, Germany. The facility contains a cannabis distribution hut which Emblem Germany will operate.
Acnos’ co-owner and Emblem Germany’s Managing Director, Maximillian Claudel, commented on the project.
“The near completion of our international cannabis distribution centre along with Emblem’s Paris facility Phase II expansion licence are breakthrough milestones toward our goal to achieve a EU-GMP Licence and receiving Emblem-produced cannabis oil products in Germany,” he said.
Aleafia Health is up 9.52 per cent, and is trading for $0.69 per share, as of 1:05pm EDT.